



Company Contact:
Jie Du, Ph.D.
President & CEO
JDP THERAPEUTICS, INC.
Email: jiedu@jdptherapeutics.com
www.jdptherapeutics.com

Carlos A. Camarco, M.D., Dr.P.H., Joins JDP's Medical Advisory Board

BLUE BELL, PENNSYLVANIA, December 2, 2013 – JDP Therapeutics Inc., a privately held specialty pharmaceutical company, is pleased to announce that Carlos A. Camarco, M.D., Dr.P.H., a renowned expert in Emergency Medicine clinical research, has joined JDP Therapeutics' Medical Advisory Board. Dr. Camarco will be providing key clinical trial guidance in the field of emergency medicine and providing support to the Company's Phase III clinical trials for JDP-205 in the Emergency Department setting for the treatment of acute allergic reactions.

Dr. Carlos A. Camarco is a Professor of Medicine at Harvard Medical School, Professor of Epidemiology at Harvard School of Public Health, and an emergency physician at the Massachusetts General Hospital in Boston (USA).

Dr. Camarco founded and directs the Emergency Medicine (EM) Network (EMNet), an international research collaboration involving >200 medical centers, specializing in clinical trials under the EM setting. EMNet focuses on respiratory/allergy emergencies, emergency care health policy, and other related public health issues. His research also focuses on nutrition and respiratory/allergy disorders in several large cohort studies and randomized trials. The health effects of obesity and vitamin D deficiency are active areas of investigation.

Dr. Camarco is past president of the American College of Epidemiology and has served on many national committees (including the 2005 US dietary guidelines, 2007 NIH asthma guidelines, and 2010 NIH food allergy guidelines). He has >500 peer-reviewed publications.

About JDP-205

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will

offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years.

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.